Lexogen Research Award – “Controlling RNA-Seq Experiments Using SIRVs“
We have received a large number of applications with very diverse and exciting projects proposals. After very careful evaluation we are happy to announce the winners of the Lexogen Research Award – “Controlling RNA-Seq Experiments Using SIRVs”:
Institution: Wellcome Trust – Medical Research Council – Cambridge Stem Cell Institute
Recommendation program: Dr. Brian Hendrich
Mary K. Thompson
Institution: University of Oxford
Recommendation program: Ana Palanca
Institution: University of Dundee
Each of the winners will receive a Spike-in RNA Variant Control Mixes (SIRVs) and 1 lane of Illumina HiSeq 2500 with 2 x 125 bp reads.
Apply or Recommend – Simply everyone can win!
Sequencing has become one of the most powerful tools in state of the art research projects. Lexogen is dedicated to the development of innovative technologies that empower next generation sequencing (NGS). As much as we care about innovations, we also believe that it is important to give all scientists the opportunity to benefit from our technologies.
With the Lexogen Research Award we wish to provide a chance for researchers to utilize NGS technologies in their upcoming projects.
We started our first Research Award “Expression Profiling by Sequencing” last spring which was very successful and received an extremely high number of applications with interesting project proposals. Out of these, three winners were selected. This September we are very happy to launch the second Research Award and look forward to your application.
We ask you to submit a project proposal that involves NGS and Lexogen’s Spike-in RNA Variant Control Mixes (SIRVs) before November 21, 2016. The three selected winners shall be given one set of SIRVs together with one sequencing run (1 lane of Illumina HiSeq 2500 with 2×125 bp reads).
The topic of this Research Award is “Controlling RNA-Seq Experiments Using SIRVs”.
Hardly anyone would run an RNA gel without a ladder, but transcriptomes are mostly sequenced without the use of external standards. The added layer of transcript isoform complexity in eukaryotes as well as incomplete or incorrect gene annotations further challenge RNA-Seq pipelines to correctly calculate and compare gene expression values.
As a specialized transcriptomics company, Lexogen addresses this problem by providing Spike-in RNA Variant Control Mixes (SIRVs) to the RNA-Seq community.
These controls are processed together with the RNA sample to allow for an evaluation of the RNA-Seq workflow and, in particular, of transcript isoform detection and gene expression quantification. The mixes contain 69 transcript variants that map to 7 human model genes and mirror the native transcriptome complexity by comprehensively representing splicing isoforms, transcription start-site and end-site variants, overlapping transcripts and antisense transcription.
Learn more about SIRVs on its web page: https://www.lexogen.com/sirvs/
Attend the SIRVs webinar on October 19, 2016. Register here.
Three applications will be chosen as the winners, and shall be given the following prizes.
Courtesy of Illumina, Inc.
1 lane run of illumina HiSeq 2500 with 2 x 125 bp reads
Who Can Apply
Any individual researcher or group in academic institutions or research organizations will be eligible for the award. Please note that official organizational email address will be needed for the application.
If the current topic of the award does not fit to your research, but you know researchers whose work does fit to the topic, you can still benefit from this award. You can choose to do either one of the followings:
- Let our Scientific Liaison, Birgit Steinmetz (firstname.lastname@example.org), know the research group. She will contact them personally to see if they wish to apply. If they do, we will count you as the recommender for that application.
- Tell them to write your name in the recommender section of the application form.
If the recommended person wins the award, you will receive a special prize – pizza treat for your lab.
The selection of the winners shall be done by 3 referees, based on the relevance of utilizing the SIRVs for the project.
Dr. Michael Quail
Wellcome Trust Sanger Institute, UK
Dr. Gene Yeo
University of California, San Diego, USA
Dr. James Hadfield
Head of Genomics at CRUK Cambridge Institute, University of Cambridge, UK
James got his degree and PhD at the University of East Anglia. He started his career with a BigC funded project to develop a diagnostic test for Her2 positive breast cancer in 1995. In 2000 he set-up one of the first microarray facilities in the UK and has focused on genomics technologies ever since. James has two kids and lives in Norfolk, which is a lot nearer the coast than Cambridge.
The application process is closed. The winners announcement will be on December 5, 2016.